Paolo Tarantino, Research Fellow presso Dana-Farber Cancer Institute, shared a post on LinkedIn:
“ADCs make chemotherapy more active through improved delivery. But do they make chemotherapy more tolerable?
Usually not. For several reasons, only understood in part.
Of these reasons, and multiple other aspects of ADC toxicities, we will discuss at the 3rd annual ADC Toxicity Summit, held in Boston MA between July 8-10. Hope to see you there.”
